Esperion Reports Fourth Quarter and Full Year 2023 Financial

– FY23 U.S. Net Product Revenue Grew 40% Y/Y to $78.3 Million; FY23 Total Revenue Grew 54% Y/Y to $116.3 Million – – Q4 U.S. Net Product Revenue Grew 39% Y/Y to $20.8 Million; Q4 Total...

Related Keywords

Spain , Australia , Hong Kong , Canada , Japan , United States , Czech Republic , American , Alexis Callahan , Daiichi Sankyo Asia , Daiichi Sankyo Europe , Sheldon Koenig , Tiffany Aldrich , Esperion Therapeutics Inc , American Heart Association Scientific Sessions , National Health Insurance , Exchange Commission , Product Revenue Grew , Revenue Grew , Prescription Equivalents Grew , Momentum Expected , Resolved Litigation , Potential Cost Savings , Additional Revenue Streams , Recent Positive Interactions , Proposed Indications , Secondary Prevention , Cardiovascular Risk , Conference Call , Webcast Today , Full Year , Heart Association Scientific , Sankyo Asia , South Central American , Japan New Drug Application , Fiscal Year , Esperion Therapeutics , Adverse Event , Contact Information , Markets ,